dc.contributor.author |
Cairns, MJ |
en |
dc.contributor.author |
Carland, M |
en |
dc.contributor.author |
McFadyen, DW |
en |
dc.contributor.author |
Denny, William |
en |
dc.contributor.author |
Murray, V |
en |
dc.date.accessioned |
2011-11-18T02:17:36Z |
en |
dc.date.issued |
2009 |
en |
dc.identifier.citation |
Journal of Inorganic Biochemistry 103(8):1151-1155 2009 |
en |
dc.identifier.issn |
0162-0134 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/9393 |
en |
dc.description.abstract |
Cisplatin analogues with an attached DNA binding moiety have a higher affinity for DNA, but often suffer from poor aqueous solubility. In this study we examined the DNA sequence specificity of more soluble cisplatin analogues containing the maltolato leaving group in both purified DNA and in intact human cells. In both environments the DNA sequence specificity of these analogues was very similar to cisplatin. However, in purified DNA a higher concentration of the two maltolato-containing analogues was needed to achieve a similar level of DNA damage as cisplatin. This difference in reactivity was not observed in intact cells as the two maltolato-containing complexes were capable of producing a similar level of damage as cisplatin at comparable concentrations. This was consistent with the IC50 values obtained for both cisplatin and the maltolato compounds which were also similar. This study indicated that maltolato can be utilised as the leaving group to increase the aqueous solubility of cisplatin analogues without reducing their biological activity. |
en |
dc.language |
EN |
en |
dc.publisher |
Elsevier B.V. |
en |
dc.relation.ispartofseries |
Journal of Inorganic Biochemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from
http://www.sherpa.ac.uk/romeo/issn/0162-0134/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Diammineplatinum(II) |
en |
dc.subject |
Maltolato |
en |
dc.subject |
Sequence selectivity |
en |
dc.subject |
Human cells |
en |
dc.subject |
PLATINUM PHENANTHRIDINIUM COMPLEXES |
en |
dc.subject |
ANTICANCER DRUGS |
en |
dc.subject |
SPECIFICITY |
en |
dc.subject |
DAMAGE |
en |
dc.title |
The DNA sequence selectivity of maltolato-containing cisplatin analogues in purified plasmid DNA and in intact human cells |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.jinorgbio.2009.06.001 |
en |
pubs.issue |
8 |
en |
pubs.begin-page |
1151 |
en |
pubs.volume |
103 |
en |
dc.rights.holder |
Copyright: Elsevier B.V. |
en |
dc.identifier.pmid |
19586662 |
en |
pubs.end-page |
1155 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
88903 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
19586662 |
en |